Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name FGFR2 positive
Gene Variant Detail

FGFR2 positive (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 positive Advanced Solid Tumor sensitive Aprutumab ixadotin Preclinical - Pdx & cell culture Actionable In a preclinical study, sensitivity to Aprutumab ixadotin (BAY1187982) positively correlated with Fgfr2 expression level in a variety of cancer cell lines in culture, and in cell line or patient-derived xenograft models (PMID: 27543601). 27543601
FGFR2 positive stomach cancer sensitive Aprutumab ixadotin Preclinical - Pdx & cell culture Actionable In a preclinical study, Aprutumab ixadotin (BAY1187982) inhibited survival of gastric cancer cell lines with elevated Fgfr2 expression level in culture, and suppressed tumor growth in cell line or patient-derived xenograft models (PMID: 27543601). 27543601
FGFR2 positive breast cancer sensitive Aprutumab ixadotin Preclinical - Pdx & cell culture Actionable In a preclinical study, Aprutumab ixadotin (BAY1187982) inhibited survival of Fgfr2 positive breast cancer cell lines in culture, and suppressed tumor growth in both cell line and patient-derived xenograft models (PMID: 27543601). 27543601
FGFR2 positive breast cancer predicted - sensitive Rogaratinib Case Reports/Case Series Actionable In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR2-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741). detail...
FGFR2 positive triple-receptor negative breast cancer sensitive Alofanib Preclinical - Cell culture Actionable In a preclinical study, Alofanib (RPT835) treatment led to inhibition of cell proliferation in triple-receptor negative breast cancer cell lines expressing FGFR2 in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27136102). 27136102
FGFR2 positive ovarian cancer predicted - sensitive Alofanib Preclinical - Cell culture Actionable In a preclinical study, Alofanib (RPT835) inhibited growth in an ovarian cancer cell line expressing FGFR2 in culture (PMID: 27136102). 27136102